Skip to main content
Elsevier
View Cart

Therapies for Treatment-Resistant Depression

Neuropharmacology and Neurostimulation

  • 1st Edition - August 5, 2025
  • Latest edition
  • Editors: James Murrough, Dennis Charney
  • Language: English

Therapies for Treatment-Resistant Depression: Neuropharmacology and Neurostimulation provides readers with an authoritative, comprehensive and targeted treatment guide. The first… Read more

World Book Day celebration

Where learning shapes lives

Up to 25% off trusted resources that support research, study, and discovery.

Explore resources

Description

Therapies for Treatment-Resistant Depression: Neuropharmacology and Neurostimulation provides readers with an authoritative, comprehensive and targeted treatment guide. The first section reviews the essential knowledge and methods of clinical neuroscience and neuropsychopharmacological techniques as they apply to novel treatment discovery for depression. This is followed by detailed chapters on ketamine, esketamine, other glutamate modulators in development, GABA modulators, neuropeptides, anti-inflammatory agents, and other classes of novel therapeutics under study for TRD and related mood disorders.

The last section consists of a set of chapters of special interest that includes current and future research directions, development of psilocybin-based interventions and other psychedelic compounds currently under study for TRD and advances in biomarker-guided and personalized treatment. Edited by world renowned experts in the field, this book is the ultimate resource for researchers and clinicians.

Key features

  • Defines treatment-resistant depression, including epidemiology
  • Outlines neuroimaging and brain-based biomarkers in treatment-resistant depression using patient data
  • Reviews safety and monitoring protocols of ketamine in clinical care

Readership

practicing psychiatrists and other providers in allied mental health fields, researchers and scientists in psychiatry and neuroscience in academic and industry, psychiatry and medical residents and postdoctoral fellows in psychiatry and clinical neuroscience programs, graduate students in biomedical research

Table of contents

1. Treatment-Resistant Depression: Epidemiology and Clinical Presentation

2. Molecular Neuropharmacology of Treatment-Resistant Depression

3. Neurobiology and Neuroimaging of Treatment-Resistant Depression

4. Pharmacotherapy of Treatment-Resistant Depression: Overview and Look Ahead

5. Lithium, Dopamine Modulators, and Other Augmentation Strategies for Treatment-Resistant Depression

6. Ketamine and Esketamine for Treatment-Resistant Depression

7. The Impact of Inflammation on Treatment Resistance in Depression: Mechanisms and Translational Opportunities

8. Novel Pharmacotherapies for Treatment-Resistant Depression: A Focus on Glutamate and GABA Modulators

9. Electroconvulsive Therapy for Treatment-Resistant Depression

10. Transcranial Magnetic Stimulation for Treatment-Resistant Depression

11. Vagal Nerve Stimulation for Treatment-Resistant Depression

12. Deep Brain Stimulation for Treatment-Resistant Depression

13. Psilocybin and Other Psychedelic Agents in Development for Treatment-Resistant Depression

14. Neuroimaging Biomarkers in Treatment Selection for Treatment-Resistant Depression

15. The Role of Genetics in Treatment-Resistant Depression

Product details

  • Edition: 1
  • Latest edition
  • Published: August 6, 2025
  • Language: English

About the editors

JM

James Murrough

I am Professor of Psychiatry and Neuroscience, Vice Chair for Clinical Research in Psychiatry, and Director of the Depression and Anxiety Center for Discovery and Treatment (DAC) at the Icahn School of Medicine at Mount Sinai (ISMMS). My program of research utilizes molecular, neuroimaging, and experimental therapeutics approaches aimed at elucidating the fundamental mechanisms underlying stress-related disorders in humans, including major depressive disorder (MDD), posttraumatic stress disorder (PTSD) and anxiety disorders. The overall goal of my research is to advance the treatment of stress-related disorders through an enhanced understanding of disease pathogenesis and therapeutic mechanisms of action.
Affiliations and expertise
Professor of Psychiatry and Neuroscience, Vice Chair for Clinical Research in Psychiatry, and Director of the Depression and Anxiety Center for Discovery and Treatment, Icahn School of Medicine at Mount Sinai (ISMMS), New York, NY, USA

DC

Dennis Charney

Dennis S. Charney is an American biological psychiatrist and researcher, with expertise in the neurobiology and treatment of mood and anxiety disorders. He is the author of Neurobiology of Mental Illness, The Physician's Guide to Depression and Bipolar Disorders and Molecular Biology for the Clinician, as well as the author of over 600 original papers and chapters. In 2022, he was listed #52 on Research.com's "Top Medicine Scientists in the United States," with an h-index of 194 with 146,109 citations across 651 publications. Charney is known for demonstrating that ketamine is effective for treating depression. Ketamine's use as a rapidly-acting anti-depressant is recognized as a breakthrough treatment in mental illness.
Affiliations and expertise
The Anne and Joel Ehrenkranz Dean, Icahn School of Medicine at Mount Sinai, New York, NY, USA

View book on ScienceDirect

Read Therapies for Treatment-Resistant Depression on ScienceDirect